Food Allergy Treatment Market Report Scope & Overview:

The Food Allergy Treatment Market was valued at USD 7.57 Billion in 2025 and is expected to reach USD 18.29 Billion by 2035, growing at a CAGR of 9.23% from 2026 to 2035.

The international community within the healthcare sector keeps on experiencing an increasing trend towards the development of new treatments of food allergies that would provide a much-needed solution to the problems of hundreds of millions of people all over the world. The number of people with food allergies is estimated at around 250 million people across the globe and their symptoms vary from mild to even fatal anaphylaxis. Among those important market drivers that will support future growth are an increasing prevalence rate of food allergies and growing R&D efforts for the development of new pharmaceutical products, among others.

Stallergenes Greer announced in August 2025 that it will voluntarily discontinue PALFORZIA by July 31, 2026, not due to safety, quality, or efficacy concerns, with the company committing to fulfill regulatory obligations and support a smooth transition for patients and healthcare providers currently relying on the treatment.

Market Size and Forecast

• Market Size in 2026E: USD 8.27 Billion
• Market Size by 2035: USD 18.29 Billion
• CAGR: 9.23% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information Food Allergy Treatment Market - Request Free Sample Report

Food Allergy Treatment Market Trends

• Oral immunotherapy and biologics continue showing promise in desensitization for peanut and other common food allergies.
• Increasing funding for allergy treatments continues driving advancements in research, development, and accessibility of innovative therapies.
• A significant proportion of the food allergy burden continues being associated with comorbid atopic conditions including asthma and atopic dermatitis.
• Personalized medicine approaches continue improving patient adherence and satisfaction across food allergy treatment protocols.
• Growing awareness of food-related anaphylaxis and enhanced diagnostic capabilities continue reshaping patient care and management practices.

The United States Food Allergy Treatment Market Outlook

The United States Food Allergy Treatment Market was valued at USD 2.57 Billion in 2025 and is expected to reach USD 6.08 Billion by 2035, growing at a CAGR of 9.00% from 2026 to 2035.

Market for treating food allergy in the US keeps growing at a very lucrative pace due to the fact that the country spends heavily on its health care and has a well developed healthcare infrastructure. As per Food Allergy Research and Education group, there are six point one million cases of peanut allergy in the US, which makes the demand for treatments related to this particular type of allergen very strong.

Mitsubishi Gas Chemical partnered with Alerje in 2024 to enhance global allergy care, strengthening the availability of allergy management technology and solutions for patients and healthcare providers across the United States market.

Food Allergy Treatment Market Segmentation Analysis

• By Drug Type, the epinephrine segment held approximately 41.00% share in the food allergy treatment market in 2025, while the biologics segment is the fastest growing.
• By Route of Administration, the parenteral segment held approximately 54.90% share in the food allergy treatment market in 2025, while the oral segment is the fastest growing.
• By Allergen Type, the peanuts segment held approximately 20.55% share in the food allergy treatment market in 2025, while the tree nuts segment is the fastest growing.
• By End-User, the hospitals segment held the largest share in the food allergy treatment market in 2025, while the homecare segment is the fastest growing.

By Drug Type, epinephrine segment dominates the food allergy treatment market, while biologics grows fastest

The Epinephrine segment held approximately 41.00% of total market revenue in 2025, considered the medication of choice for treatment of allergic conditions owing to its use as the initial treatment for emergency allergic reactions. That established role as the frontline emergency treatment continues to keep epinephrine firmly at the top of the broader drug type segmentation across nearly every major food allergy management protocol worldwide.

The Biologics segment is projected to grow at the fastest CAGR during the forecast period, as biological agents including Xolair continue demonstrating promise in desensitization approaches for peanut and other common food allergies. Rising adoption of biologics for both treatment and prevention applications continues pushing this drug type category's growth rate ahead of the broader drug type segmentation.

By Route of Administration, parenteral segment dominates the food allergy treatment market, while oral grows fastest

The parenteral segment held approximately 54.90% of total market revenue in 2025, reflecting the established role that injectable epinephrine plays in emergency anaphylaxis treatment across both clinical and self-administered settings. That established emergency treatment role continues to keep the parenteral route firmly at the top of the broader route of administration segmentation.

The oral segment is projected to grow at the fastest CAGR during the forecast period, as oral immunotherapy continues gaining traction as a desensitization approach, with FDA approvals including Palforzia having expanded access to structured oral treatment programs. Rising patient and physician interest in oral desensitization protocols continues pushing this route of administration category's growth rate ahead of the broader route of administration segmentation.

By Allergen Type, peanuts segment dominates the food allergy treatment market, while tree nuts grows fastest

The peanuts segment held approximately 20.55% of total market revenue in 2025, driven by peanut allergies' high prevalence and severity, particularly among children. Treatments including oral immunotherapy and biologics continue showing promise in desensitization for this allergen category, keeping peanuts firmly at the top of the broader allergen type segmentation across nearly every major regional market worldwide.

The tree nuts segment is projected to grow significantly during the forecast period, as rising diagnosis rates and growing treatment options for this allergen category continue expanding the addressable patient population. Continued research and development investment targeting tree nut desensitization protocols continues pushing this allergen type category's growth rate ahead of the broader allergen type segmentation.

By End-User, hospitals segment dominates the food allergy treatment market, while homecare grows fastest

The hospitals segment held the largest share of the end-user segmentation in 2025, anchored by the clinical supervision that emergency anaphylaxis treatment and structured oral immunotherapy programs require. That established clinical infrastructure requirement continues to keep hospitals firmly at the top of the broader end-user segmentation.

The homecare segment is projected to grow at the fastest CAGR during the forecast period, as self-administered epinephrine auto-injectors and maintenance-phase oral immunotherapy protocols continue expanding treatment options available outside clinical settings. Rising patient preference for home-based allergy management continues pushing this end-user category's growth rate ahead of the broader end-user segmentation.

Regional Analysis

North America Food Allergy Treatment Market Insights

North America held the largest share of the global food allergy treatment market in 2025, at approximately 40.50%, driven by high healthcare expenditure and advanced healthcare infrastructure across the region. Rising prevalence of food allergies and increasing research and development activity for novel drugs continued reinforcing this leadership position throughout the year.

The United States accounted for roughly 84.80% of regional revenue, reflecting its concentration of leading food allergy treatment developers and comprehensive healthcare reimbursement infrastructure. Canada contributed a smaller but steadily growing share of regional revenue, supported by its own expanding food allergy treatment adoption, keeping North America firmly ahead of every other region in this market.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Food Allergy Treatment Market Insights

The European region had a considerable market share in the world food allergy treatments market in 2025 owing to well-developed health insurance systems and robust infrastructure for pharmaceutical research within Europe. The country with the highest share of revenue is Germany with nearly 27.40%, due to the presence of many biopharmaceutical firms in the country.

The United Kingdom and France followed a broadly similar trajectory, as continued investment in allergy treatment research extended food allergy treatment adoption across the continent's largest healthcare markets. Continued regulatory support for novel immunotherapy approvals is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific Food Allergy Treatment Market Insights

Asia Pacific was the fastest-growing region in the global food allergy treatment market, supported by rising food allergy diagnosis rates and expanding healthcare infrastructure investment across the region's largest and most populous economies. Growing awareness of food-related anaphylaxis continued driving regional demand at a pace considerably faster than more mature Western markets.

China accounted for roughly 36.60% of regional revenue, supported by expanding domestic healthcare infrastructure and growing food allergy awareness campaigns. Japan and South Korea contributed significant additional regional demand through their own advanced healthcare technology adoption, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America Food Allergy Treatment Market Insights

The Middle East and Africa region recorded steady growth in food allergy treatment adoption in 2025, driven by expanding healthcare infrastructure investment and growing government support for allergy management programs across the Gulf states in particular. The UAE accounted for roughly 26.50% of regional revenue, supported by national healthcare modernization strategies and rising demand for advanced allergy treatment options.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.30% of regional revenue, where growing healthcare infrastructure investment continued to support category growth. Mexico and Argentina followed a similar trajectory as regional food allergy treatment adoption expanded further through the remainder of the forecast period.

Growth Drivers: Rising Global Prevalence and Novel Drug Development Investment

The rising prevalence of food allergies worldwide, affecting approximately two hundred fifty million people globally, continues to be the central force behind food allergy treatment market growth. Increasing research and development activities for novel drugs, combined with the adoption of new biological agents to treat food allergies, continue reinforcing structural demand growth across nearly every major regional healthcare market worldwide.

An increase in clinic visits by patients seeking therapy for food allergies, combined with rising funding for allergy treatment research, continues driving advancements in accessibility of innovative therapies. Growing awareness of food-related anaphylaxis and enhanced diagnostic capabilities continue reinforcing sustained market expansion through the forecast period.

Restraints: Treatment Discontinuations and High Therapy Costs

Voluntary treatment discontinuations, exemplified by Stallergenes Greer's decision to discontinue PALFORZIA, continue creating genuine disruption for patients and healthcare providers who must transition to alternative treatment options. That transition burden continues requiring careful coordination between manufacturers, physicians, and patients to maintain treatment continuity.

The high cost of biologics and structured oral immunotherapy programs continues restricting adoption among price-sensitive patient populations and healthcare systems with constrained reimbursement frameworks. That cost barrier continues concentrating the most advanced food allergy treatment options within higher-income markets and well-insured patient populations.

Opportunities: Biologics Pipeline Expansion and Tree Nut Allergen Targeting

Continued clinical pipeline development for biological agents targeting food allergy desensitization presents substantial opportunity for manufacturers positioned to serve patients seeking alternatives to epinephrine-only emergency management. Manufacturers capable of delivering genuinely effective, well-tolerated biologics stand to capture a growing share of demand as this treatment category continues expanding.

Growing diagnosis rates and treatment options for tree nut allergies present a further significant growth avenue, as this allergen category continues gaining dedicated research and development attention. Manufacturers capable of delivering tree nut-specific desensitization protocols stand to capture meaningful new revenue streams through 2035.

Recent Developments:

• 2026: Novartis indicated in its fourth quarter 2025 presentation that initiation of the Phase III program for remibrutinib is anticipated in the second half of 2026, advancing its food allergy treatment pipeline.
• 2024: Inimmune entered into a collaboration with Intrommune Therapeutics to develop oral immunotherapy for peanut allergies, combining both companies' research capability toward a shared treatment goal.
• 2024: The United States Food and Drug Administration approved Xolair for severe allergies, expanding treatment access for patients managing food allergy risk alongside other allergic conditions.

Food Allergy Treatment Market key players are:

• Sanofi
• Aimmune Therapeutics
• DBV Technologies
• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• COUR Pharmaceuticals
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• ARS Pharmaceuticals, Inc.
• ALK-Abelló A/S
• Alfresa Holdings Corporation
• Stallergenes Greer
• Aravax Pty Ltd
• Aquestive Therapeutics, Inc.
• Mitsubishi Gas Chemical Company, Inc.
• Alerje, Inc.
• Inimmune Corporation
• Intrommune Therapeutics, Inc.
• GlaxoSmithKline plc
• Genentech, Inc.

Food Allergy Treatment Market Report Scope :